These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30104788)

  • 1. Treatment of people diagnosed with chronic hepatitis C virus infection.
    Bulterys M; Sadiq Hamid S
    Bull World Health Organ; 2018 Aug; 96(8):515. PubMed ID: 30104788
    [No Abstract]   [Full Text] [Related]  

  • 2. The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.
    Seto WK; Tanaka Y; Liu K; Lai CL; Yuen MF
    Am J Gastroenterol; 2011 May; 106(5):1007-8. PubMed ID: 21540909
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Dual Genotype Chronic Hepatitis C: Case Series.
    Jha LK; Gilbert J
    Dig Dis Sci; 2016 Aug; 61(8):2451. PubMed ID: 27048453
    [No Abstract]   [Full Text] [Related]  

  • 4. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments.
    Cobb B; Vilchez RA
    Hepatology; 2012 Mar; 55(3):979-80; author reply 980-1. PubMed ID: 22161994
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 6. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
    Ghany MG; Nelson DR; Strader DB; Thomas DL; Seeff LB;
    Hepatology; 2011 Oct; 54(4):1433-44. PubMed ID: 21898493
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of chronic hepatitis B and C virus infections in the clinical practice].
    Panther E; Thimme R
    Praxis (Bern 1994); 2012 Jan; 101(1):37-42. PubMed ID: 22219073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine.
    Stasi C; Silvestri C; Voller F; Cipriani F
    J Infect Public Health; 2016; 9(4):389-95. PubMed ID: 26148849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity of genotype and mode of spread of Hepatitis C virus in Northern India.
    Rehan HS; Manak S; Yadav M; ; Chopra D; Wardhan N
    Saudi J Gastroenterol; 2011; 17(4):241-4. PubMed ID: 21727729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
    Khan AJ; Saraswat VA; Ranjan P; Parmar D; Negi TS; Mohindra S
    J Med Virol; 2019 Apr; 91(4):659-667. PubMed ID: 30431653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus-related chronic hepatitis with reference to the genotype.
    Belloni G; Ferrari L; Balduzzi C; Barbieri F; Insolia R; Klersy C
    Ital J Gastroenterol Hepatol; 1999; 31(5):427. PubMed ID: 10470605
    [No Abstract]   [Full Text] [Related]  

  • 12. Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C.
    Ramachandran P; Hayes PC
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):259-61. PubMed ID: 22646248
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic genotype 4 hepatitis C.
    Schafer DF
    Hepatology; 2008 May; 47(5):1791-2; author reply 1793-4. PubMed ID: 18395844
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic hepatitis C genotype 2 or 3 short treatment.
    Moreno-Otero R; Trapero M; Moreno-Monteagudo JA
    Hepatology; 2008 May; 47(5):1796. PubMed ID: 18438810
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
    Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
    Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals.
    Backus LI; Shahoumian TA; Belperio PS; Winters M; Prokunina-Olsson L; O'Brien TR; Holodniy M
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):34-36. PubMed ID: 29866411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
    World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: a hardwiring issue?
    Tai AW; Chung RT
    J Infect Dis; 2009 Apr; 199(8):1101-3. PubMed ID: 19284288
    [No Abstract]   [Full Text] [Related]  

  • 19. [MiR-196a-2 gene polymorphism and the antiviral therapy of chronic hepatitis C].
    Hong XL; Cao H; Zhao F; Pan XF; Zhang K; Xu QH; Zhao ZX; Li G
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Dec; 24(6):470-2. PubMed ID: 21604580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
    Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
    Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.